Athira Pharma, Inc. (ATHA): Business Model Canvas [Apr-2026 Updated]

You're looking at Athira Pharma, Inc. right now, and honestly, it's a textbook case of a clinical-stage company at a major inflection point: they've staked their near-term future on advancing ATH-1105 for ALS while actively exploring strategic alternatives with Cantor Fitzgerald. Given their cash position of $25.2 million at the end of Q3 2025, and with operating expenses running about $6.9 million that quarter (that's $2.8 million in R&D plus $4.1 million in G&A), the runway demands a successful outcome from this strategic review. This Business Model Canvas distills exactly where their resources are focused-from their unique HGF modulation platform to their zero commercial revenue-so you can map the risk against the potential disease-modifying value they aim to deliver to patients and shareholders. Dive in below to see the full nine blocks of their current operation.

Athira Pharma, Inc. (ATHA) - Canvas Business Model: Key Partnerships

You're looking at Athira Pharma, Inc. (ATHA)'s external relationships as they navigate the path forward with ATH-1105, especially after pausing the fosgonimeton program. The structure of these alliances is critical for managing cash burn and advancing the pipeline.

The exploration of strategic alternatives, which began after the LIFT-AD trial results for fosgonimeton, directly involves a key financial partner.

• Cantor Fitzgerald & Co. was engaged to act as an advisor for exploring strategic alternatives focused on maximizing stockholder value.

This advisory role is set against a backdrop of the company's current financial standing as of mid-2025. Here's a quick look at the balance sheet context surrounding these activities:

The development focus has clearly shifted to ATH-1105, and the company is actively looking outward for support to progress this candidate, particularly for the next stage of clinical work.

Regarding clinical execution and future development, Athira Pharma, Inc. is positioning itself for collaboration:

• Athira Pharma, Inc. has paused further development of fosgonimeton, including its related open label extension clinical trial.
• The company is continuing the development of ATH-1105 and is actively exploring partnering options for this asset.
• Preparation activities are substantially complete to enable the initiation of a future clinical trial in people living with ALS, either conducted by Athira Pharma, Inc. itself or 'in conjunction with a partner.'

While the specific names of Contract Research Organizations (CROs) used for the completed Phase 1 trial of ATH-1105 (NCT 06432647) or the academic research centers involved in US and European studies are not detailed in the latest public updates, the structure anticipates a partner for the upcoming ALS trial.

The search for potential pharmaceutical partners is directly tied to the future of ATH-1105, which is being positioned as a treatment for neurodegenerative diseases including ALS, Alzheimer's disease, and Parkinson's disease. The company is looking for a partner to help advance ATH-1105, especially given the current cash position and the need to fund the next clinical steps.

Athira Pharma, Inc. (ATHA) - Canvas Business Model: Key Activities

You're looking at the core things Athira Pharma, Inc. (ATHA) is actively doing to keep the lights on and move its science forward as of late 2025. The focus is clearly on the ALS candidate, ATH-1105, while managing a tight financial runway.

Advancing the ATH-1105 clinical program for ALS

The main push is advancing ATH-1105, which is designed to positively modulate the neurotrophic hepatocyte growth factor (HGF) system, aiming for neuroprotection and anti-inflammation in the central nervous system (CNS). This drug candidate is also being explored for Alzheimer's disease and Parkinson's disease, though the immediate clinical focus is ALS.

The initial human testing is complete, supporting the next steps. Here are the key activity metrics for ATH-1105 as of the Q3 2025 update:

The company is also managing the pipeline, which includes next-generation small molecule drug candidates. To be fair, the development of the prior candidate, fosgonimeton (ATH-1017), has been paused following the topline results of the LIFT-AD trial in September 2024.

Exploring strategic alternatives to maximize stockholder value

Following the LIFT-AD trial results in September 2024, Athira Pharma, Inc. formally began looking at different paths to maximize stockholder value. This is a major ongoing key activity.

• Engaged Cantor Fitzgerald & Co. to act as an advisor for the process.
• The exploration is continuing as of the Q3 2025 report.

Proprietary small molecule drug discovery and preclinical development

This activity centers on the core science: developing small molecules that modulate the neurotrophic HGF system. The preclinical data for ATH-1105 is what continues to support its clinical advancement.

The preclinical evidence for ATH-1105 has demonstrated statistically significant improvements in:

• Nerve and motor function.
• Biomarkers of inflammation and neurodegeneration.
• Survival in various models of ALS.

Managing intellectual property and regulatory filings

While specific patent or filing numbers aren't in the latest earnings release, the progression of ATH-1105 through the Phase 1 trial and the presentation of data at key conferences like ALS Nexus 2025 are direct outputs of successful IP and regulatory management supporting clinical execution. The company is focused on advancing the program to get to the next regulatory hurdle, which is dosing ALS patients.

Executing significant cost reduction and operational streamlining

Athira Pharma, Inc. has definitely been executing on streamlining operations, which is reflected starkly in the year-over-year expense comparison for the third quarter ending September 30, 2025. This is defintely a critical activity given the cash position.

Here's the quick math on the expense reduction for Q3 2025 versus Q3 2024 (amounts in thousands):

The company previously estimated that layoffs of around 70% of its workforce would save approximately $13.4 million in costs on an annualized basis. Furthermore, the company executed a 10-for-1 reverse stock split effective on September 17, 2025. The cash position as of September 30, 2025, stood at $25.2 million, down from $51.3 million at the end of 2024. Net cash used in operations for the nine months ending September 30, 2025, was $26.3 million, compared to $71.2 million for the same period in 2024.

Athira Pharma, Inc. (ATHA) - Canvas Business Model: Key Resources

You're looking at the core assets Athira Pharma, Inc. (ATHA) relies on to execute its strategy as of late 2025. These aren't just line items; they are the tangible and intangible things that make the business run.

Financially, the immediate resource is the balance sheet strength, though it's clearly under pressure given the clinical stage. Cash, cash equivalents, and investments stood at $25.2 million as of September 30, 2025. This compares to $51.3 million at the end of 2024. The net cash used in operations for the nine months ending September 30, 2025, was $26.3 million.

The most critical resources are the proprietary drug candidates and the platform underpinning them. Athira Pharma, Inc. is focused on small molecules designed to positively modulate the neurotrophic HGF system (Hepatocyte Growth Factor system).

The pipeline resources include:

• ATH-1105: A next-generation, orally available small molecule candidate for potential treatment of Amyotrophic Lateral Sclerosis (ALS).
• ATH-1020: An orally available small molecule candidate that showed promise in preclinical models for reducing pain in diabetic neuropathy.
• Fosgonimeton (ATH-1017): Development was paused following the topline results of the LIFT-AD trial in September 2024.

The platform itself is a key intangible asset. Athira Pharma, Inc.'s proprietary drug discovery platform is designed to develop novel therapeutic candidates that promote regeneration and provide neuroprotection by acting on the HGF system. This platform has generated preclinical evidence supporting its small molecule candidates for a range of neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and ALS.

The company also had to address past issues impacting its IP credibility. Athira Pharma, Inc. agreed to pay $4,068,698 in January 2025 to settle False Claims Act allegations related to failing to report research misconduct concerning its former CEO's doctoral research.

The management team provides the necessary expertise to navigate this complex environment. Here's a look at some key personnel:

The team is tasked with advancing ATH-1105, which completed its Phase 1 healthy volunteer trial in November 2024, showing a favorable safety profile and CNS penetration. The goal was to begin dosing ALS patients in 2025. Still, the exploration of strategic alternatives, advised by Cantor Fitzgerald & Co., remains a key management focus to bolster the financial position.

The status of the lead candidate, ATH-1105, is a primary resource driver. As of late 2025, data from its Phase 1 trial showed it was well tolerated and had dose proportional pharmacokinetics. That data supports the continued development for ALS.

Finance: draft 13-week cash view by Friday.

Athira Pharma, Inc. (ATHA) - Canvas Business Model: Value Propositions

You're looking at the core promise Athira Pharma, Inc. (ATHA) offers to patients and the market. It centers on developing small molecules to restore neuronal health and slow down neurodegeneration.

Potential to restore neuronal health and slow neurodegeneration

The fundamental value proposition is the potential to alter the course of neurological diseases. Athira Pharma, Inc. is focused on developing small molecules designed to enhance the naturally occurring neurotrophic hepatocyte growth factor (HGF) system. Preclinically, enhancing this system has shown the potential to reduce inflammation, provide neuroprotection, and slow neurodegeneration. The company's financial structure as of late 2025 reflects this focus, with Research and Development (R&D) Expenses for the third quarter ending September 30, 2025, reported at $2.8 million.

Developing an orally available, brain-penetrant therapy (ATH-1105) for ALS

The lead asset, ATH-1105, is positioned as a novel, orally available, brain-penetrant, next-generation small molecule drug candidate specifically for Amyotrophic Lateral Sclerosis (ALS). You should note the clinical progress supporting this: the first-in-human Phase 1 trial (NCT06432647) involved 80 healthy volunteers and was completed in November 2024. Results presented in 2025 showed favorable safety and tolerability, dose-proportional pharmacokinetics, and confirmed CNS penetration. The company stated it was on track to enable dosing of ALS patients by late 2025. Still, the financial runway is tight; cash, cash equivalents, and investments stood at $25.2 million as of September 30, 2025.

Novel mechanism of action targeting the neurotrophic HGF system

The mechanism is key here: promoting the neurotrophic HGF system activates pathways that are neuroprotective, neurotrophic, and anti-inflammatory within the central nervous system. Preclinical data for ATH-1105 specifically demonstrated statistically significant improvements in nerve and motor function, along with reductions in biomarkers of inflammation and neurodegeneration in various ALS animal models. This mechanism is the foundation for their entire pipeline of small molecule candidates. Here's a quick look at the recent financial context surrounding this development effort:

Disease-modifying potential for a broad range of neurological disorders

Athira Pharma, Inc. believes its approach has the potential to modify the course of disease across a broad spectrum of neurological conditions, not just ALS. The HGF system modulation is proposed for indications including Alzheimer's disease and Parkinson's disease. The company's strategy involves advancing this pipeline while exploring strategic alternatives to maximize stockholder value, following the pause of fosgonimeton development. The Q3 2025 net loss was $1.68 per share. You're looking at a platform play, not just a single asset.

• Orally available drug candidates.
• Targeting neuroprotective and anti-inflammatory pathways.
• Preclinical data showing improved function and survival markers.
• Exploring potential for Alzheimer's disease and Parkinson's disease.

Finance: draft 13-week cash view by Friday.

Athira Pharma, Inc. (ATHA) - Canvas Business Model: Customer Relationships

Direct engagement with clinical investigators and research institutions centers on advancing the ATH-1105 program for ALS.

• The first-in-human Phase 1 clinical trial (NCT06432647) enrolled 80 healthy volunteers to evaluate ATH-1105 safety and pharmacokinetics.
• The company was on-track to enable dosing ALS patients in late 2025.
• The Phase 1 study was completed in November 2024.

Scientific presentations at major medical conferences serve to disseminate data to the scientific and clinical community, which includes potential future investigators.

• Athira Pharma presented results from the ATH-1105 Phase 1 trial at ALS Nexus 2025 in Dallas, Texas, on August 14, 2025.
• Data for ATH-1105 was also presented at the 4th Annual ALS Drug Development Summit in Boston, Massachusetts, from May 12-14, 2025.
• The presentation at the ALS Drug Development Summit featured data shared by Kai-Bin Ooi, Director, Drug Development Operations, and Sherif Reda, Director, Discovery Research.
• Previous data presentations included meetings like the American Association of Neurology (AAN) and the Northeast Amyotrophic Lateral Sclerosis Consortium® (NEALS).

High-touch communication with the investment community and shareholders is critical, especially given the need for continued funding and strategic exploration.

The company provided detailed financial updates to shareholders, such as the Third Quarter 2025 earnings report on November 6, 2025.

Investor relations focused heavily on pipeline progress and strategic updates following key data releases.

• Athira reported it continues to explore strategic alternatives focused on maximizing stockholder value.
• The company engaged Cantor Fitzgerald & Co. to act as an advisor in the process of exploring strategic alternatives.
• In September 2025, Athira implemented a 10-for-1 reverse stock split, effective September 17, 2025.
• Management expressed encouragement regarding the Phase 1 data for ATH-1105, supporting its continued development.
• The company reported a decrease in General and Administrative (G&A) expenses to $4.1 million for Q3 2025, down from $7.6 million for Q3 2024.

Athira Pharma, Inc. (ATHA) - Canvas Business Model: Channels

You're looking at how Athira Pharma, Inc. (ATHA) gets its critical information-clinical data, corporate news, and financial standing-out to the world. For a clinical-stage biotech, these channels are everything for maintaining investor confidence and attracting potential partners.

Clinical trial sites in the United States and Europe

The physical channel for generating primary data centers on clinical trial sites. As of late 2025, the focus is clearly on advancing ATH-1105 for ALS.

• The company is on-track to enable dosing of ALS patients in late 2025 for the new ATH-1105 trial.
• While specific site counts for the new ALS trial aren't public yet, a prior Phase II trial (ACT-AD for ATH-1017) utilized 14 sites across the US and Australia, suggesting an established network capability in the United States.
• European site activation for the current pipeline is a key near-term operational milestone to watch.

Scientific publications and medical conference presentations

This is where Athira Pharma, Inc. validates its science. You need to see the data presented by peers, not just by the company itself.

The year 2025 saw key dissemination points for the Phase 1 data on ATH-1105:

• Presentation of ATH-1105 Phase 1 Trial Results at the ALS Nexus 2025 conference in August 2025.
• Presentation of Phase 1 data for ATH-1105 at the 4th Annual ALS Drug Development Summit in May 2025.

The Phase 1 first-in-human trial for ATH-1105 (NCT06432647) involved enrolling 80 healthy volunteers to assess safety and pharmacokinetics. That's a solid early-stage data package to build on.

Investor relations website and SEC filings for corporate updates

This is the official, regulated channel for financial and material corporate news. You should check these first for any decision-making data.

Key filings and website presence include:

• The primary investor portal is located at investors.athira.com.
• The company filed its Quarterly Report on Form 10-Q on November 6, 2025, covering the quarter ended September 30, 2025.
• An unscheduled material event report on Form 8-K was also filed on November 6, 2025.

Press releases and news wires (e.g., GlobeNewswire)

Press releases, often distributed via services like GlobeNewswire, are the immediate public notification system for material events. Athira Pharma, Inc. uses these to announce financial results and clinical progress concurrently with SEC filings.

Notable 2025 press release dates include:

• November 6, 2025: Third Quarter 2025 Financial Results and Business Update.
• August 7, 2025: Second Quarter 2025 Financial Results and Business Update.
• May 9, 2025: First Quarter 2025 Financial Results and Pipeline Updates.

Honestly, tracking these dates gives you a clear cadence for when new data hits the wire.

Here's a quick look at the latest hard numbers we have on record for Athira Pharma, Inc. channels and financials:

Finance: draft Q4 2025 cash flow projection by next Tuesday.

Athira Pharma, Inc. (ATHA) - Canvas Business Model: Customer Segments

You're looking at Athira Pharma, Inc. (ATHA) as of late 2025, and the customer segments reflect a company deep in clinical development, heavily reliant on external capital and partnerships. The focus is clearly on the clinical pipeline, specifically ATH-1105.

Patients with Amyotrophic Lateral Sclerosis (ALS) for lead candidate ATH-1105

This group represents the ultimate end-users for the therapeutic benefit. Athira Pharma, Inc. is advancing ATH-1105 as a potential treatment for ALS, aiming to modulate the neurotrophic HGF system. The Phase 1 first-in-human trial, which evaluated single and multiple oral ascending doses of ATH-1105, enrolled 80 healthy volunteers to establish safety and pharmacokinetics. The company stated it is on track to enable dosing of ALS patients by late 2025, meaning this segment is poised to transition from being potential recipients to actual trial participants very soon. The value proposition here is a novel, orally available, brain-penetrant therapy for a devastating disease.

Pharmaceutical and biotech companies for potential licensing or acquisition

These entities are critical customers for Athira Pharma, Inc.'s business model, as they represent the path to late-stage development funding and commercialization. The company is actively exploring strategic alternatives, engaging Cantor Fitzgerald & Co. as an advisor to facilitate this process. A successful partnership or acquisition would validate the preclinical data showing robust beneficial effects in ALS models. The financial context is important here: Athira Pharma, Inc. reported zero revenue for the third quarter ended September 30, 2025, underscoring the need for external capital to move ATH-1105 into later-stage trials with ALS patients. Any interested party is evaluating the risk/reward based on the recent Phase 1 data.

Investors and shareholders seeking high-risk, high-reward biotech exposure

This segment provides the necessary equity financing to sustain operations until a liquidity event. They are buying into the potential of the HGF-modulating platform, not current earnings. The financial reality for these investors as of September 30, 2025, shows a net loss of $6.6 million for the quarter. The cash position was $25.2 million as of that date, down from $51.3 million at the end of 2024, with net cash used in operations totaling $26.3 million for the nine months ended September 30, 2025. This burn rate and cash balance define the near-term funding risk. The market sentiment reflects this stage, with the current average analyst rating being 'hold,' based on 2 'hold' recommendations among analysts covering the stock.

The recent financial performance highlights the operational focus:

Healthcare providers and neurologists treating neurodegenerative diseases

These professionals are key opinion leaders and future prescribers, whose validation is crucial for market adoption post-approval. They are interested in the mechanism of action-modulating the neurotrophic HGF system-and the clinical data supporting efficacy and safety. Athira Pharma, Inc. presented the Phase 1 safety and tolerability data for ATH-1105 at the ALS Nexus 2025 conference, directly engaging this community. Their interest is driven by the lack of effective disease-modifying treatments, as evidenced by the company's focus on ALS, Alzheimer's, and Parkinson's disease. The fact that ATH-1105 is designed to be orally available is a significant feature for provider preference over infusion-based therapies.

• Engaging experts at ALS Nexus 2025.
• Evaluating oral dosing profile for patient convenience.
• Seeking therapies that improve survival and quality of life.
• Preclinical data showed improvements in motor function.

Finance: draft 13-week cash view by Friday.

Athira Pharma, Inc. (ATHA) - Canvas Business Model: Cost Structure

You're looking at the core expenses Athira Pharma, Inc. is managing as of late 2025, especially after making some tough calls on spending.

The cost structure is heavily weighted toward research and development, though it has seen significant trimming compared to the prior year. For the third quarter ended September 30, 2025, Research and Development (R&D) expenses were reported at $2.8 million. This represents a substantial reduction from the $17.9 million recorded in the same quarter of 2024.

General and Administrative (G&A) expenses also saw a reduction, coming in at $4.1 million for Q3 2025, down from $7.6 million in Q3 2024. Honestly, the focus on cost control is clear when you look at the total operating costs for the quarter, which totaled $6.87 million.

Here's a quick look at those key quarterly costs:

The costs associated with exploring strategic alternatives are not itemized as a direct expense in the quarterly filing, but the engagement of Cantor Fitzgerald & Co. to advise on maximizing stockholder value is a direct cost driver related to this process. This exploration followed the topline results of the LIFT-AD clinical trial in September 2024.

Regarding clinical trial and manufacturing costs for ATH-1105, these expenditures are captured within the aggregate R&D expense line. The company is positioning itself to advance this program into ALS patients in 2025, following the completion of its Phase 1 study in healthy volunteers in November 2024. The R&D spend of $2.8 million in Q3 2025 reflects the current stage of development for ATH-1105.

Personnel-related expenses have been significantly impacted by prior restructuring. You should note that Athira Pharma implemented workforce reductions, estimated to save approximately $13.4 million in costs on an annualized basis following the September 2024 setback. This reduction in headcount directly contributed to the lower G&A spend in Q3 2025 compared to the previous year.

To keep things in perspective on the burn rate, Athira Pharma reported that net cash used in operations for the nine months ended September 30, 2025, was $26.3 million. The cash position, cash equivalents, and investments stood at $25.2 million as of September 30, 2025.

The primary cost drivers are:

• Research and Development activities for ATH-1105.
• General overhead and operational support.
• Advisory fees related to the strategic review.

Finance: draft 13-week cash view by Friday.

Athira Pharma, Inc. (ATHA) - Canvas Business Model: Revenue Streams

You're looking at the revenue structure for Athira Pharma, Inc. (ATHA) as a clinical-stage biopharmaceutical company in late 2025. The current reality is that the company is not generating sales from approved products.

Currently $0 in commercial product revenue as a clinical-stage company. For the quarter ended September 30, 2025, Athira Pharma, Inc. reported revenue of zero; analysts also expected zero revenue for that period.

Potential future revenue from strategic transactions or asset sales is a key focus right now. Athira Pharma, Inc. management stated they continue to explore strategic alternatives focused on maximizing stockholder value. The company engaged Cantor Fitzgerald & Co. to act as an advisor in this process.

Potential future revenue from licensing agreements for drug candidates is contingent on successful development. The lead candidate, ATH-1105, is being advanced for the potential treatment of amyotrophic lateral sclerosis (ALS). The Phase 1 clinical trial in healthy volunteers demonstrated a favorable safety and tolerability profile, along with dose proportional pharmacokinetics and CNS penetration, supporting continued clinical development. Athira Pharma, Inc. was on track to enable dosing of ALS patients by late 2025.

Future product sales if ATH-1105 achieves regulatory approval represent the ultimate long-term revenue stream. ATH-1105 is designed to positively modulate the neurotrophic hepatocyte growth factor (HGF) system.

Here's a quick look at the recent financial performance that underpins the current operating model, which is focused on R&D and strategic review rather than sales:

The structure of potential future revenue is tied directly to pipeline progression and transaction success. You can think of the near-term revenue drivers as:

• Exploring strategic alternatives to maximize stockholder value.
• Potential upfront payments or milestones from future licensing agreements for drug candidates like ATH-1105.
• Achieving regulatory approval for ATH-1105 to enable future product sales.

The company is definitely focused on advancing ATH-1105 while managing cash burn, which was $6.61 million in net loss for the third quarter of 2025. Finance: draft 13-week cash view by Friday.